Literature DB >> 10953056

Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors.

S D Donevan1, R T McCabe.   

Abstract

Conantokin G (Con G) is a 17-amino-acid peptide antagonist of N-methyl-D-aspartate (NMDA) receptors isolated from the venom of the marine cone snail, Conus geographus. The mechanism of action of Con G has not been well defined; both competitive and noncompetitive interactions with the NMDA-binding site have been proposed. In this study the mechanism of action and subunit selectivity of Con G was examined in whole-cell voltage-clamp recordings from cultured neurons and in two electrode voltage-clamp recordings from Xenopus oocytes expressing recombinant NMDA receptors. Con G was a potent and selective antagonist of NMDA-evoked currents in murine cortical neurons (IC(50) = 480 nM). The slow onset of Con G block could be prevented by coapplication with high concentrations of NMDA or of the competitive antagonist (RS)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid. Furthermore, in oocytes expressing NR1a/NR2B receptors, Con G produced a rightward shift in the concentration-response curve for NMDA, providing support for a competitive interaction with the NMDA-binding site. Con G produced an apparent noncompetitive shift in the concentration-response curve for spermine potentiation of NMDA responses, but this was due to spermine-induced enhancement of Con G block. Spermine produced a similar enhancement of DL-2-amino-S-phosphopentanoic acid block. Finally, Con G selectively blocked NMDA receptors containing the NR2B subunit. These results demonstrate that Con G is a subunit-specific competitive antagonist of NMDA receptors. The unique subunit selectivity profile of Con G may explain its favorable in vivo profile compared with nonselective NMDA antagonists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953056     DOI: 10.1124/mol.58.3.614

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  32 in total

Review 1.  Marine pharmacology in 2000: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Mark T Hamann
Journal:  Mar Biotechnol (NY)       Date:  2003-11-03       Impact factor: 3.619

2.  Opposing action of conantokin-G on synaptically and extrasynaptically-activated NMDA receptors.

Authors:  Rashna Balsara; Neill Li; Danielle Weber-Adrian; Louxiu Huang; Francis J Castellino
Journal:  Neuropharmacology       Date:  2012-01-27       Impact factor: 5.250

3.  Conantokins derived from the Asprella clade impart conRl-B, an N-methyl d-aspartate receptor antagonist with a unique selectivity profile for NR2B subunits.

Authors:  Konkallu Hanumae Gowd; Tiffany S Han; Vernon Twede; Joanna Gajewiak; Misty D Smith; Maren Watkins; Randall J Platt; Gabriela Toledo; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Biochemistry       Date:  2012-05-30       Impact factor: 3.162

Review 4.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

5.  Non-strict strand orientation of the Ca2+-induced dimerization of a conantokin peptide variant with sequence-shifted gamma-carboxyglutamate residues.

Authors:  Qiuyun Dai; Cai Xiao; Mingxin Dong; Zhuguo Liu; Zhenyu Sheng; Francis J Castellino; Mary Prorok
Journal:  Peptides       Date:  2009-01-24       Impact factor: 3.750

6.  Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatum.

Authors:  Roy M Smeal; Kristen A Keefe; Karen S Wilcox
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

7.  Delayed secondary phase of peri-infarct depolarizations after focal cerebral ischemia: relation to infarct growth and neuroprotection.

Authors:  Jed A Hartings; Michael L Rolli; X-C May Lu; Frank C Tortella
Journal:  J Neurosci       Date:  2003-12-17       Impact factor: 6.167

8.  Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists.

Authors:  Jitendra R Dave; Anthony J Williams; John R Moffett; Michael L Koenig; Frank C Tortella
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins.

Authors:  Cai Xiao; Yuanyuan Huang; Mingxin Dong; Jie Hu; Shuangshuang Hou; Francis J Castellino; Mary Prorok; Qiuyun Dai
Journal:  Neuropeptides       Date:  2008-11-07       Impact factor: 3.286

Review 10.  Ligands for ionotropic glutamate receptors.

Authors:  Geoffrey T Swanson; Ryuichi Sakai
Journal:  Prog Mol Subcell Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.